Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients

12.03.2014 / Fierce Pharma

Payers are growing increasingly balky at the price Gilead Sciences slapped on its breakthrough hepatitis C pill Sovaldi. An expert panel in California that assesses new treatments voted Sovaldi a "low value" treatment–not because it doesn't work well enough, but because of its $1,000-a-pill price tag.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: